Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jun;118(3):711–719. doi: 10.1111/j.1476-5381.1996.tb15458.x

Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.

A Hilditch 1, H M Prior 1, G M Drew 1
PMCID: PMC1909712  PMID: 8762098

Abstract

1. The angiotensin AT1 receptor antagonist, GR138950, produces a long-lasting antihypertensive effect in conscious renal artery ligated hypertensive (RALH) rats but this effect does not correlate temporally with its antagonist profile against angiotensin II (AII). In the present experiments we have compared the inhibitory profiles of GR138950 and enalapril, against angiotensin I (AI), with their respective antihypertensive activities. 2. GR138950 (1 mg kg-1, i.a.) and enalapril (3 mg kg-1, i.a.) reduced blood pressure in RALH rats to a similar degree. Maximum reductions in blood pressure occurred approximately 5-24 h and 3-5 h after administration, respectively. The antihypertensive effect of GR138950 lasted for 24-48 h. However, the effect of enalapril lasted for only 5-24 h. 3. In conscious normotensive rats, inhibition of AI-induced pressor responses was maximal 1 h after systemic administration of GR138950 and enalapril. Dose-response curves to AI were displaced to the right, in a parallel manner, 1406 and 102 fold by GR138950 (1 mg kg-1, i.a.) and enalapril (3 mg kg-1 i.a.), respectively. The inhibitory effect of enalapril lasted for < 24 h whereas that of GR138950 lasted for up to 48 h. 4. Contractile responses to AI were extensively inhibited in aortae removed from either RALH rats or normotensive rats, 1 and 5 h after administration of GR138950 (1 mg kg-1, i.a.). Responses were still significantly reduced 24 h after administration but had returned to control levels after 48 h. Enalapril pretreatment (3 mg kg-1, i.a.) did not inhibit contractile responses to AI in aortae isolated from normotensive rats at any time point. 5. These experiments confirm that GR138950 is an effective and long-lasting antihypertensive agent. GR138950 was a more potent and longer lasting antagonist against AI than has previously been found against AII, and the duration of its antihypertensive activity coincides better with its blockade of responses to AI. Blockade of the effects of AII generated locally within the vascular wall might play an important role in the antihypertensive profile of GR138950.

Full text

PDF
711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caldwell P. R., Seegal B. C., Hsu K. C., Das M., Soffer R. L. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976 Mar 12;191(4231):1050–1051. doi: 10.1126/science.175444. [DOI] [PubMed] [Google Scholar]
  2. Campbell D. J., Ziogas J., Kladis A. Metabolism of tetradecapeptide, angiotensinogen and angiotensin I and II by isolated perfused rat hindlimbs. Clin Exp Pharmacol Physiol. 1990 May;17(5):335–350. doi: 10.1111/j.1440-1681.1990.tb01330.x. [DOI] [PubMed] [Google Scholar]
  3. Cangiano J. L., Rodríguez-Sargent C., Martínez-Maldonado M. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J Pharmacol Exp Ther. 1979 Feb;208(2):310–313. [PubMed] [Google Scholar]
  4. Chiu A. T., McCall D. E., Price W. A., Wong P. C., Carini D. J., Duncia J. V., Wexler R. R., Yoo S. E., Johnson A. L., Timmermans P. B. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990 Feb;252(2):711–718. [PubMed] [Google Scholar]
  5. Dzau V. J. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987 Jan 23;59(2):59A–65A. doi: 10.1016/0002-9149(87)90178-0. [DOI] [PubMed] [Google Scholar]
  6. Eglème C., Cressier F., Wood J. M. Local formation of angiotensin II in the rat aorta: effect of endothelium. Br J Pharmacol. 1990 Jun;100(2):237–240. doi: 10.1111/j.1476-5381.1990.tb15788.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  8. Gruetter C. A., Ryan E. T., Lemke S. M., Bailly D. A., Fox M. K., Schoepp D. D. Endothelium-dependent modulation of angiotensin II-induced contraction in blood vessels. Eur J Pharmacol. 1988 Jan 27;146(1):85–95. doi: 10.1016/0014-2999(88)90489-x. [DOI] [PubMed] [Google Scholar]
  9. Hilditch A., Hunt A. A., Gardner C. J., Twissell D. J., Polley J., Travers A., Drew G. M., Middlemiss D., Ross B. C., Robertson M. J. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist. Br J Pharmacol. 1994 Jan;111(1):137–144. doi: 10.1111/j.1476-5381.1994.tb14035.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hilditch A., Hunt A. A., Travers A., Polley J., Drew G. M., Middlemiss D., Judd D. B., Ross B. C., Robertson M. J. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist. J Pharmacol Exp Ther. 1995 Feb;272(2):750–757. [PubMed] [Google Scholar]
  11. Kifor I., Dzau V. J. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res. 1987 Mar;60(3):422–428. doi: 10.1161/01.res.60.3.422. [DOI] [PubMed] [Google Scholar]
  12. Ohlstein E. H., Gellai M., Brooks D. P., Vickery L., Jugus J., Sulpizio A., Ruffolo R. R., Jr, Weinstock J., Edwards R. M. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther. 1992 Aug;262(2):595–601. [PubMed] [Google Scholar]
  13. Panek R. L., Lu G. H., Overhiser R. W., Major T. C., Hodges J. C., Taylor D. G. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther. 1995 May;273(2):753–761. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES